Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681501 | 1.00 | OPRL1 (0.51) | OPRL1OPRM1 | |
| SCHEMBL7568888 | 1.00 | OPRL1 (0.51) | OPRL1OPRM1 | |
| SCHEMBL31092767 | 0.89 | OPRL1 (0.41) | OPRL1OPRM1 | |
| SCHEMBL31092768 | 0.89 | OPRL1 (0.41) | OPRL1OPRM1 | |
| SCHEMBL705456 | 0.88 | ACE (0.55) | — | |
| SCHEMBL31092820 | 0.88 | ACE (0.55) | — | |
| SCHEMBL29443087 | 0.88 | ACE (0.55) | — | |
| SCHEMBL3702462 | 0.88 | ACE (0.55) | — | |
| SCHEMBL927332 | 0.88 | ACE (0.55) | — | |
| SCHEMBL29545684 | 0.88 | ACE (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259505-B1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-6596732-B2 | Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. | SANOFI-SYNTHELABO (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-06-12 | — | — | US | disclosed |
| EP-1259505-A2 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064668-A2 | 1,3-DIHYDRO-2H-INDOL-2-ONE, AND THEIR USE AS V1B OR BOTH V1B AND V1A ARGININE-VASOPRESSIN LIGAND RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | AVPR2, AVPR1B, AVPR1A | OPRL1 106/4885OPRM1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.